Company news
Cosmo Pharmaceuticals NV news in 2026
Cosmo Pharmaceuticals NV's news releases, calls and decks from 2026, newest first.
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
August 14, 2026
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
July 23, 2026
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
July 1, 2026
Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany
June 15, 2026
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
June 11, 2026
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
May 18, 2026
Cosmo N Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program (EN)
May 18, 2026
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
April 15, 2026
Voting Results of Cosmo's 2026 AGM
April 10, 2026
AGM – 10 April 2026 – Voting Results
April 9, 2026
AGM – 10 April 2026 – Minutes
April 9, 2026
AGM – 10 April 2026 – Distribution Information
April 9, 2026
Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026
March 16, 2026
Cosmo Presents Agenda for AGM 2026
March 12, 2026
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
March 9, 2026
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
March 5, 2026
Cosmo to Participate in Upcoming Investor Conferences
February 18, 2026
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
February 3, 2026
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
January 28, 2026
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
January 12, 2026